Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Pentixapharm Holding AG Stock

Price
Target price
€2.06

€2.06

0.000%
-
0.000%
-

-

 
Buy 1 Sell 0
Buy 1
Sell 0
19:54 / Tradegate WKN: A40AEG / Name: Pentixapharm Holding / Stock / ? /
Latest predictions
16.09.25
21.75%
buy
Show more
Best running prediction
-
16.09.25
21.75%
buy
Your prediction
Pros and Cons of Pentixapharm Holding AG in the next few years
Wizard

Pentixapharm Holding AG Stock

There is no change in the price for Pentixapharm Holding AG today.
What does Pentixapharm Holding do?

Pros and Cons of Pentixapharm Holding AG in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice
Register To Post

News

EQS-News: Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
EQS-News: Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
EQS-News: Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
eqs_en 
0 31.03.26
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
eqs_en 
0 19.03.26
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
eqs_en 
0 25.02.26